"With as much as $17 billion in sales in 2024 and over $10 billion in the first half of 2025, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S ( NYSE: NVO). This Scandinavian economic behemoth is one of the highest-valued companies in Europe at over $500 billion, which exceeds Denmark's entire gross domestic product. Ironically, Ozempic and Wegovy, like many of Novo Nordisk's other products, were created primarily for treating diabetes."
"After coming to the United States in 1982, it underwent several corporate changes until becoming Novo Nordisk in 1989. In addition to diabetes drugs, the company also makes drug treatments for wound healing, menopausal hormone replacement, and human growth hormone. Besides Ozempic and Wegovy, the company has made progress recently on other obesity drugs in its pipeline, including amycretin and CagriSema."
Novo Nordisk achieved as much as $17 billion in sales from Ozempic in 2024 and over $10 billion in the first half of 2025, driving unprecedented growth. The company is valued at over $500 billion, exceeding Denmark's gross domestic product. Ozempic and Wegovy were developed primarily to treat diabetes, with weight loss emerging as a profitable unintended side effect. Founded a century ago, the company originally made insulin and became Novo Nordisk in 1989. The firm produces treatments for diabetes, wound healing, menopausal hormone replacement, and human growth hormone. The obesity pipeline includes amycretin (Phase 1) and CagriSema (Phase 2), and the company expects the obesity market to reach $100 billion by 2030.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]